anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Childbirth may be associated with psychological, social, and emotional effects and provide the background for women's health or illness throughout their life. This research aimed at comparing the impact of non-pharmacological pain relief and pharmacological analgesia with remifentanil on childbirth fear and postpartum depression.
MATERIALS AND METHOD: This randomized clinical trial with two parallel arms was conducted on 66 women with term pregnancy referred to Taleghani Hospital in Tabriz for vaginal delivery during September 2022 to September 2023. First, all of the eligible participants were selected through Convenience Sampling. Then, they were randomly assigned into two groups of pharmacological analgesia with remifentanil and non-pharmacological analgesia with a ratio of 1:1 using stratified block randomization based on the number of births. Before the intervention, fear of childbirth (FOC) was measured using Delivery Fear Scale (DFS) between 4 and 6 cm cervical dilatation. Pain and fear during labor in dilatation of 8 cm were measured in both groups using VAS and DFS. After delivery, FOC was assessed using Delivery Fear Scale (W DEQ Version B) and postpartum depression using the Edinburgh's postpartum depression scale (EPDS). Significance level was considered 0.05. Mean difference (MD) was compared with Independent T-test and ANCOVA pre and post intervention.
RESULTS: The mean score of FOC in the non-pharmacological analgesia group was significantly lower than that in the pharmacological analgesia group after the intervention by controlling the effect of the baseline score (MD: -6.33, 95%, Confidence Interval (CI): -12.79 to -0.12, p = 0.04). In the postpartum period, the mean score of FOC in the non-pharmacological analgesia group was significantly lower than that in the pharmacological analgesia group after controlling the effect of the baseline score (MD: -21.89; 95% CI: -35.12 to -8.66; p = 0.002). The mean score of postpartum depression in the non-pharmacological analgesia group was significantly lower than that in the pharmacological analgesia group (MD: -1.93, 95% CI: -3.48 to -0.37, p = 0.01).
TRIAL REGISTRATION: Iranian Registry of Clinical Trials (IRCT): IRCT20170506033834N10. Date of registration: 05/07/2022 Date of first registration: 05/07/2022. URL: https://www.irct.ir/trial/61030; Date of recruitment start date05/07/2022.
CONCLUSION: The study results indicated a reduction in FOC and postpartum depression among parturient women receiving non-pharmacological strategies with active participation in childbirth compared to women receiving pharmacological analgesia. Owing to the possible side effects of pharmacological methods for mother and fetus, non-pharmacological strategies with active participation of the mother in childbirth are recommended to reduce the FOC and postpartum depression.
The present invention relates to a human body washing composition including a wormwood extract. More specifically, the present invention relates to a human body washing composition including natural essential oil and hydrosol of wormwood including one or more selected from the group consisting of Artemisia annua L., Artemisia selengensis TURCZ., Mt. Jodo Artemisia argyi Lev. et Sav., and Mt. Geomundo Artemisia argyi Lev. et Sav.. The human body washing composition of the present invention contains natural essential oil and hydrosol of wormwood, thereby having remarkably excellent functional effects in applying aromatherapy to a user, ensuring antibacterial properties, soothing skin, moisturizing skin, whitening skin, and ensuring elasticity. Moreover, a human body washing composition of the present invention, specifically, a body shampoo composition has remarkably excellent physical quality such as viscosity, flexibility, and fragrance palatability and using sensation such as washing power, bubbling power, and spreading power.
After being informed about the study and potential risks, all participants who gave written consent will undergo the study. A randomized controlled trial with pre-/post-study, of 42 stroke patients with upper limb weakness (21 patients in the control group and 21 patients in the intervention group), 18-65 years old, all are newly admitted stroke patients in the rehabilitation clinic from one hospital. Participants in the intervention group will receive 60 minutes of VR training to improve upper limb function and daily living activities. Participants in the control group will receive 60 minutes of conventional training to improve upper limb function and daily living activities. The training includes grasp, grip, pinch, gross, and finger-hand coordination movement. The training will perform 5 times/week for 4 weeks. Two outcome measures: (a) The Barthel Index and (b) The Fugl-Meyer Assessment, time spent to complete a task were used to compare two groups.
Chemotherapy-related fatigue (CRF) occurs universally in cancer patients which can be a debilitating symptom that affects patients' quality of life. The impact of CRF has been associated with mood disorder, sleep disturbance, cognitive dysfunction, inflammation mediated putative biological disturbances, and functional morbidities. Although the etiology is heterogeneous and complex, one of the proposed mechanisms is that chemotherapy induced multiple oxidative degradation of the lipid membrane which generates reactive oxygen species (ROS) and tissue damage. These conditions result in inflammation-induced reduction in central dopaminergic neurotransmission, nutritional deficiency (especially in vitamins and minerals), and immunodeficiency, which clinically manifest as CRF. To date, various agents including psychostimulants (methylphenidate, donepezil, and modafinil), dexamethasone, and Korean red ginseng (KRG) were used in the management of CRF. However, the prevalence of CRF is still high primarily due to lack of proven effective therapies. ALDH enzyme supplementation plays an essential role in the eliminates 4-hydoxynonenal, malondialdehyde from lipid peroxidation and reduce ROS bioactivation, which can protect and relieve CRF in cancer patients. Based on these rational backgrounds, the aim or this study is to evaluate the efficacy and safety of ALDH enzyme in CRF with advanced gastrointestinal cancer patients.
PURPOSE: A composition containing a novel compound is provided to ensure antibacterial and antifungal activities and to be used in foods, cosmetic products, and pharmaceutical products. CONSTITUTION: A compound is denoted by chemical formula 1. A composition with antibacterial and antifungal activities contains the compound of chemical formula 1 as an active ingredient. The composition has antibacterial activity against Bacillus sp., Micrococcus sp., Streptococcus sp., Staphylococcus sp., Enterococcus sp., Listeria sp., Pseudomonas sp., Salmonella sp. or E.coli. A preservative contains the composition containing the compound of chemical formula 1 as an active ingredient. A composition for treating or preventing fungal diseases contains the composition containing the compound as an active ingredient.
<P>PROBLEM TO BE SOLVED: To provide a treatment device, a treatment system and a method for controlling the treatment system, which enables to perform an advanced medical treatment to emergency patients in medical facilities where medical specialists are absent.  <P>SOLUTION: A first facility 61 where an emergency patient 51 and a medical assistant 52 are provided is provided with an image data acquisition part 1, a TV camera 4 and a treatment part 2. The image data of the emergency patient 51 obtained by the image data acquisition part 1 and the TV camera 4 is transmitted to a second facility 62 where a medical specialist (doctor 53) is provided through transmitting and receiving parts 11, 21 which communicates the medical information. After confirming that the preparation for treatment is completed based on the image data displayed on an image display part 23, the doctor 53 at the second facility 62 inputs a treatment performing signal into an input part of treatment performing signal 27. The treatment performing signal is transmitted to the receiving part 10 of treatment performing signal at the first facility 61 through the transmitting and receiving parts 11, 21 and the treatment by the treatment part 2 is instructed.  <P>COPYRIGHT: (C)2004,JPO
The present invention relates to a medical practice collection and management system and method. A method according to the present invention comprises the steps of: obtaining voice and image data generated from a medical practice process; assigning a class code according to a predetermined classification system with respect to each of a plurality of intervals contained in the obtained voice and image data; and storing information to which the class code is assigned with respect to the plurality of intervals. The present invention stores the medical practice process recorded in voices and images by a code, thereby skipping a medical record process by professional personnel and a conventional patient classification system process and directly classifying the medical practice process by a code. In addition, the present invention converts moving picture information, which is voice and image data, into text codes, thereby storing the entire medical practice process in a much smaller capacity. The present invention may be easy to store and manage as compared with conventional data, and may prevent loss of patient answer and response information and the like, important in storing all the medical practice process. In addition, the present invention stores, by a code, each patient answer and response in accordance with a medical examination and physical examination by a doctor, thereby being used as a fundamental infrastructure in managing quality of the medical practice process and applying an artificial intelligence technology to the medical practice process.
BACKGROUND: Breeding of lettuce (Lactuca sativa L.), the most important leafy vegetable worldwide, for enhanced disease resistance and resilience relies on multiple wild relatives to provide the necessary genetic diversity. In this study, we constructed a super-pangenome based on four Lactuca species (representing the primary, secondary and tertiary gene pools) and comprising 474 accessions. We include 68 newly sequenced accessions to improve cultivar coverage and add important foundational breeding lines.
RESULTS: With the super-pangenome we find substantial presence/absence variation (PAV) and copy-number variation (CNV). Functional enrichment analyses of core and variable genes show that transcriptional regulators are conserved whereas disease resistance genes are variable. PAV-genome-wide association studies (GWAS) and CNV-GWAS are largely congruent with single-nucleotide polymorphism (SNP)-GWAS. Importantly, they also identify several major novel quantitative trait loci (QTL) for resistance against Bremia lactucae in variable regions not present in the reference lettuce genome. The usability of the super-pangenome is demonstrated by identifying the likely origin of non-reference resistance loci from the wild relatives Lactuca serriola, Lactuca saligna and Lactuca virosa.
CONCLUSIONS: The super-pangenome offers a broader view on the gene repertoire of lettuce, revealing relevant loci that are not in the reference genome(s). The provided methodology and data provide a strong basis for research into PAVs, CNVs and other variation underlying important biological traits of lettuce and other crops.
In this arm, participants will receive the Phase 2 and Phase 3 treatments only. The phase 2 will include 7 weeks of bevacizumab + chemoradiotherapy (IV infusion of bevacizumab alone, 2 weeks before administration of the first cycle of chemoradiotherapy, then 5 one-week cycles of chemoradiotherapy \[5-FU + radiotherapy\], with administration of bevacizumab every two weeks \[Cycles 1, 3 and 5\]) followed by a treatment-free interval of 6 to 8 weeks. The phase 3 will be surgery involving a radical rectal excision using the TME technique.
PURPOSE: A composition for preventing or treating cancer is provided to selectively suppress DNA topoisomerase II alpha. CONSTITUTION: A compound which selectively suppresses DNA topoisomerase II alpha is denoted by chemical formula 1. A method for preparing the compound of chemical formula 1 comprises: a step of reacting a compound of chemical formula 2 with epichlorohydrin to prepare a compound of chemical formula 3; and a step of reacting the compound of chemical formula 3 with HR_2. A pharmaceutical composition for preventing or treating cancer contains the compound of chemical formula 1 or a pharmaceutically acceptable salt thereof. The composition suppresses topoisomerase II alpha. The composition additionally contains a pharmaceutically acceptable carrier. The pharmaceutical composition is used for preventing or treating animals exclusive of human by administering.
Granisetron is a selective 5-hydroxytryptamine3 (5-HT3) receptor antagonist with little or no affinity for other serotonin receptors, including 5-HT1, 5-HT1A, 5-HT1B/C, 5-HT2; for alpha1-, alpha2-, or beta-adrenoreceptors; for dopamine-D2; or for histamine-H1; benzodiazepine; picrotoxin or opioid receptors. 

Serotonin receptors of the 5-HT3 type are located peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. During chemotherapy that induces vomiting, mucosal enterochromaffin cells release serotonin, which stimulates 5-HT3 receptors. This evokes vagal afferent discharge, inducing vomiting. Animal studies demonstrate that, in binding to 5-HT3 receptors, granisetron blocks serotonin stimulation and subsequent vomiting after emetogenic stimuli such as cisplatin. In the ferret animal model, a single granisetron injection prevented vomiting due to high-dose cisplatin or arrested vomiting within 5 to 30 seconds.
Bupropion inhibits the reuptake of dopamine and norepinephrine. Concomitant use of MAOIs and bupropion is contraindicated because there is an increased risk of hypertensive reactions if bupropion is used concomitantly with MAOIs. Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine. At least 14 days should elapse between discontinuation of an MAOI intended to treat depression and initiation of treatment with bupropion hydrochloride tablets. Conversely, at least 14 days should be allowed after stopping bupropion hydrochloride tablets before starting an MAOI antidepressant . [see Dosage and Administration ( , ) and Contraindications ( )] 2.42.54
INTRODUCTION: Hypertensive intracerebral hemorrhage (HICH) is a condition associated with significant morbidity, mortality, and disability, particularly among the elderly population. The management of moderate thalamic-basal ganglia cerebral hemorrhage primarily relies on conservative approaches. Nevertheless, the rate of long-term disability remains high. In recent years, there has been significant advancement in minimally invasive surgery and diffusion tensor imaging techniques. Consequently, the utilization of Diffusion Tensor Imaging (DTI) technology in patients with cerebral haemorrhage allows for the identification of the haematoma's location in relation to the Corticospinal Tract (CST). This enables the development of precise puncture pathways that can be visualized, thereby avoiding any potential damage to the CST.
METHODS AND ANALYSIS: Diffusion Tensor Imaging (DTI) is a method used to assess the structural and physiological characteristics of biological tissue by examining the diffusion behavior of water molecules.In the central nervous system, limb paralysis will be inevitable if the corticospinal tract is damaged. By employing DTI imaging techniques on individuals, it becomes possible to visualize the spatial relationship between the hematoma and the CST. This approach allows avoidance of the CST during preoperative planning of the puncture path, thus reducing secondary injuries caused by the procedure. The primary objective of this study was to assess the ability of patients in the minimally invasive surgery group and the conservative group to perform activities of daily living after 6 months of treatment. In addition, secondary outcomes included assessment of hematoma resorption/clearance ratios, cytokine levels, complication rates, and therapeutic indexes at different treatment durations, as well as long-term safety and efficacy at 2-3 years of follow-up. Furthermore, subgroup analysis, and sensitivity analysis were conducted to further analyze the data. Logistic single-variate and multivariate regression analyses were applied to understand the adverse factors affecting prognosis.
ETHICS AND DISSEMINATION: The clinical study was reviewed and approved by the Ethics Committee of the First People's Hospital of Yibin. The ethical number is: 2023 Review (64).
REGISTRATION NUMBER: This protocol is registered in the Prospective Registry of Chinese Clinical Trial Registries (PROCCTR). The full date of first registration is 28/12/2023. The registration number for PROCCTR is ChiCTR2300079252.
A genetically modified cytotoxic T cell includes one or more exogenous nucleic acid molecules encoding a transgenic antigen-targeting construct. Estrogen receptor-binding fragment-associated antigen 9 (EBAG9) activity is inhibited in the cells. The antigen-targeting construct can be a chimeric antigen receptor (CAR) or T cell receptor (TCR). The modified T cell can be used in the treatment of a proliferative disease, in particular for the treatment of hematologic malignancies. A pharmaceutical composition includes the modified T cell, a nucleic acid vector encoding the antigen-targeting construct and an inhibitor of EBAG9, such an RNA interference molecule. An in vitro method can increase the cytolytic activity of a cytotoxic T cell.
PURPOSE:To obtain the polymer which has a high mol.wt. and is highly water- sol. by mixing a monomer component mainly comprising (meth)acrylic acid with specified amts. of an alkaline ion and a water-sol. compd. and subjecting the mixture to aqueous-solution quiescent thermal polymn. CONSTITUTION:A polymerizable monomer component contg. at least 60mol% (meth)acrylic acid is mixed with at least one kind of ion selected from the group consisting of alkali and ammonium ions in an amt. of 60-120mol% based on all the acid groups in the monomer component, then mixed with at least one water-sol. compd. selected from the group consisting of ethylene glycol, propylene glycol, glycerin, a monosaccharide, a sugar alcohol, an oligosaccharide, and polyvinyl alcohol having a degree of saponification of at least 70% in an amt. of 0.01-20wt.% based on the monomer component, and subjected to aqueous-solution quiescent thermal polymn., giving the polymer useful as a poultice thickener.
Participant will receive the usual care as well as the four standardized electronic messages/week for 6 months. Two of these weekly messages will be two-way, providing the option for the participant to respond "yes" to an offer to have a nurse call them. A nurse phone call if requested will be provided with a week.
Artichoke WPC 500 mg capsules. Dose = 1000 mg (2 - 500 mg capsules) just before breakfast and 1000 mg (2 - 500 mg capsules) before dinner. Duration: daily for a period of 90 days.
Tobacco smoking is the leading cause of preventable death and disease. Although there are some FAD-approved medicines for controlling smoking, the relapse rate remains very high. Among the factors that could induce nicotine relapse, stress might be the most important one. In the last decades, preclinical studies have generated many new findings that lead to a better understanding of stress-induced relapse of nicotine-seeking. Several molecules such as α3β4 nicotinic acetylcholine receptor, α2-adrenergic receptors, cannabinoid receptor 1, trace amine-associated receptor 1, and neuropeptide systems (corticotropin-releasing factor and its receptors, dynorphine and kappa opioid receptor) have been linked to stress-induced nicotine relapse. In this review, we discuss recent advances in the neurobiology, treatment targets, and potential therapeutics of stress-induced nicotine relapse. We also discuss some factors that may influence stress-induced nicotine relapse and that should be considered in future studies. In the final section, a perspective on some research directions is provided. Further investigation on the neurobiology of stress-induced nicotine relapse will shed light on the development of new medicines for controlling smoking and will help us understand the interactions between the stress and reward systems in the brain.
BACKGROUND: Cough remains a persistent symptom in patients with idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs). To inform future research, treatment and care models, we conducted the first systematic synthesis of evidence on its associated burden.
METHODS: A literature search was performed for articles published between January 2010 and October 2023 using databases including Embase, MEDLINE and the Cochrane Library. Studies in patients with IPF and other ILDs reporting cough-related measures were eligible for inclusion. Included studies were categorised based on the types of ILD they examined and their design. Study details, patient characteristics and outcomes were extracted, and the risk of bias was assessed. A narrative synthesis approach was employed to interpret the findings.
RESULTS: Sixty-one studies were included: 33 in IPF, 18 in mixed-ILDs, six in connective tissue disease-associated-ILDs and four in sarcoidosis. Across the studies, a range of tools to assess cough and its impact were used. The most frequently used measures of cough were cough severity visual analogue scale (VAS) and objective cough counts, whereas the most frequently used health-related quality of life (HRQoL)/impact measures were the St. George's Respiratory Questionnaire (SGRQ) and Leicester Cough Questionnaire (LCQ). In IPF, studies consistently reported correlations between various cough and HRQoL measures, including between cough VAS scores and objective cough counts, LCQ scores and SGRQ scores. Similar correlations were observed in studies in other ILDs, but data were more limited. Qualitative studies in both IPF and other ILDs consistently highlighted the significant cough-related burden experienced by patients, including disruption of daily activities, fatigue and social embarrassment. Although there were no studies specifically investigating the economic burden of cough, one study in patients with fibrotic ILD found cough severity was associated with workplace productivity loss.
CONCLUSIONS: Our study underscores the heterogeneity in assessing cough and its impact in IPF and other ILDs. The findings confirm the negative impact of cough on HRQoL in IPF and suggest a comparable impact in other ILDs. Our synthesis highlights the need for standardised assessment tools, along with dedicated studies, particularly in non-IPF ILDs and on the economic burden of cough.